Cargando…

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy

BACKGROUND: The immune checkpoint blockade (ICB) targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) has been proved beneficial for numerous types of cancers, including non-small-cell lung cancer (NSCLC). However, a significant number of patients with NSCLC still fail to respond to ICB d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Chia-Sing, Lin, Ching-Wen, Chang, Ya-Hsuan, Chen, Hsuan-Yu, Chung, Wei-Chia, Lai, Wei-Yun, Ho, Chao-Chi, Wang, Tong-Hong, Chen, Chi-Yuan, Yeh, Chen-Lin, Wu, Sean, Wang, Shu-Ping, Yang, Pan-Chyr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692992/ https://www.ncbi.nlm.nih.gov/pubmed/33243934 http://dx.doi.org/10.1136/jitc-2020-001392

Ejemplares similares

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: McAuliffe, James, et al.
Publicado: (2021)

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer
por: Chen, Mei‐Chih, et al.
Publicado: (2023)

Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway
por: Zhuo, Yue, et al.
Publicado: (2022)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy
por: Deng, Biaolong, et al.
Publicado: (2022)

Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
por: Aoyama, Shota, et al.
Publicado: (2021)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
por: Sun, Yi, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
por: Biersack, Bernhard
Publicado: (2018)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response
por: Ahmed, Kazi Mokim, et al.
Publicado: (2022)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2
por: Jiang, Mengmeng, et al.
Publicado: (2022)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

HDAC9 deficiency promotes tumor progression by decreasing the CD8(+) dendritic cell infiltration of the tumor microenvironment
por: Ning, Yongling, et al.
Publicado: (2020)

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
por: Chen, Lujun, et al.
Publicado: (2022)

CD200 promotes immunosuppression in the pancreatic tumor microenvironment
por: Choueiry, Fouad, et al.
Publicado: (2020)

Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors
por: Leite, Caio Abner, et al.
Publicado: (2020)

Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer
por: Fujiwara, Kenji, et al.
Publicado: (2020)

Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance
por: Cheng, Han-Ying, et al.
Publicado: (2022)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
por: Pani, Fabiana, et al.
Publicado: (2022)

TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma
por: Shi, Yewen, et al.
Publicado: (2023)

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
por: Stirling, Elizabeth R, et al.
Publicado: (2022)

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpl2hlit0u9d30kekvrukjqvbk